CLASS II Drug recall · Reported 17 Apr 2019 · FDA Enforcement Report

Losartan Potassium # USP, 100 mg are white to off white recalled

H J Harkins is recalling Losartan Potassium # USP, 100 mg are white to off white, film coated, tear drop shaped, distributed in California. The recall was initiated on 4 Mar 2019 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesPharma Pac NDC: 76519-1033-03, Pharma Pac Lot # LTO00EW, Exp. 11/19, MFG NDC 31722-0702-30, MFG Lot # LOP17087, Exp. 11/2019.
Quantity recalled300 tablets

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-1083-2019
FDA event ID
82574
Recalling firm
H J Harkins, Grover Beach, CA
Classification
Class II
Status
Terminated
Recall initiated
4 Mar 2019
FDA classified
7 Apr 2019
Reported
17 Apr 2019
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Nitrosamine Impurity

Timeline

4 Mar 2019Recall initiated by company
7 Apr 2019Classified by FDA+34 days
17 Apr 2019Published in enforcement report+10 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

CGMP Deviations:Traces amounts of N-Nitroso N-Methyl 4- amino butyric acid (NMBA) impurity found in Active Pharmaceutical Ingredient (API).

Nitrosamines are impurities that can form during drug manufacturing or storage. Above the FDA acceptable intake limit, long-term exposure may raise cancer risk. The FDA advises patients to keep taking the medicine until they have a replacement.

Product as listed by the FDA

Losartan Potassium 100 mg Tablets # 30 Losartan potassium tablets USP, 100 mg are white to off white, film coated, tear drop shaped tablets, debossed with "H" on one side and "145" on the other side.

Where it was distributed

Product was distributed to a physician's office in California.

California

Questions about this recall

Why was it recalled?

CGMP Deviations:Traces amounts of N-Nitroso N-Methyl 4- amino butyric acid (NMBA) impurity found in Active Pharmaceutical Ingredient (API).

Which lots are affected?

Pharma Pac NDC: 76519-1033-03, Pharma Pac Lot # LTO00EW, Exp. 11/19, MFG NDC 31722-0702-30, MFG Lot # LOP17087, Exp. 11/2019.

Where was it sold?

Product was distributed to a physician's office in California.

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from H J Harkins

All 9

Other Losartan # recalls

All 98
ReportedClassRecallCompanyReasonWhere
DrugCLASS IILosartan Potassium and Hydrochlorothiazide Tablets recalledLosartan Potassium And HydrochlorothiazideMacleods Pharma USAForeign MaterialNationwide
DrugCLASS IILosartan Potassium Tablets, USP, 25 mg recalled by Strides PharmaLosartan PotassiumStrides PharmaForeign MaterialNationwide
DrugCLASS IILosartan potassium & Hydrochlorothiazide Tablets 100 mg/25 recalledLosartan Potassium And HydrochlorothiazideMacleods Pharma UsaPotency & AssayNationwide
DrugCLASS IILosartan Potassium Tablets, USP 25 mg recalled by PD-Rx PharmaceuticalsLosartan PotassiumPD-Rx PharmaceuticalsPotency & AssayNationwide
DrugCLASS IILosartan Potassium Tablets, USP 100 mg recalled by PD-Rx PharmaceuticalsLosartan PotassiumPD-Rx PharmaceuticalsPotency & AssayNationwide